TENET HEALTHCARE CORP (THC)       53.65  +2.07 (+4.01%)

53.65  +2.07 (+4.01%)

US88033G4073 - Common Stock - After market: 53.65 0 (0%)

Buy % Consensus

Analysts have set a mean price target of 94.92. This target is 76.92% above the current price.
THC was analyzed by 24 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about THC.
In the previous month the buy percentage consensus was at a similar level.
THC was analyzed by 24 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target

Price Low Median Mean High 53.6573.7392.3194.92141.75 - 37.43% 72.06% 76.92% 164.21%

Up and Down Grades

Date Firm Action Rating
2022-08-24 SVB Leerink Maintains Outperform
2022-08-02 Mizuho Maintains Buy
2022-07-28 UBS Maintains Buy
2022-07-26 Raymond James Maintains Strong Buy
2022-07-26 Citigroup Maintains Buy
2022-07-25 RBC Capital Maintains Outperform
2022-07-25 SVB Leerink Maintains Outperform
2022-07-25 Truist Securities Maintains Buy
2022-07-25 Citigroup Maintains Buy
2022-07-15 SVB Leerink Maintains Outperform
2022-07-12 Goldman Sachs Maintains Buy
2022-07-11 Raymond James Maintains Strong Buy
2022-07-07 Deutsche Bank Maintains Buy
2022-07-01 Mizuho Maintains Buy
2022-06-17 Loop Capital Initiate Buy
2022-04-25 Wells Fargo Maintains Overweight
2022-04-22 Deutsche Bank Maintains Buy
2022-04-22 RBC Capital Maintains Outperform
2022-04-22 SVB Leerink Maintains Outperform
2022-04-22 Barclays Maintains Overweight
2022-04-22 Citigroup Maintains Buy
2022-03-07 Jefferies Maintains Buy
2022-03-03 Mizuho Maintains Buy
2022-03-01 Goldman Sachs Reiterate Buy
2022-02-10 UBS Upgrade Neutral -> Buy
2022-02-09 Deutsche Bank Maintains Buy
2022-02-09 SVB Leerink Upgrade Market Perform -> Outperform
2022-02-09 Barclays Maintains Overweight
2022-02-09 Truist Securities Upgrade Hold -> Buy
2022-02-09 Credit Suisse Maintains Outperform

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA